Intranasal oxytocin vs injectable oxytocin
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
Same molecule, two completely different regulatory and evidentiary situations. This table separates what is approved and well evidenced from what is compounded and contested.
| Aspect | Injectable oxytocin (Pitocin) | Intranasal oxytocin | Source |
|---|---|---|---|
| FDA status | Approved prescription drug, NDA 018261, currently marketed | No approved product. Syntocinon nasal solution (NDA 012285) is listed Discontinued and its approval was withdrawn in 1997 at the sponsor's request | source |
| Strength as approved | 10 USP units/mL | 40 USP units/mL for the discontinued product; compounded strengths are not standardized | source |
| Labeled indications | Medically indicated induction or stimulation of labor, adjunct in incomplete or inevitable abortion, and control of postpartum bleeding | None. Every use is off-label or outside the drug regulatory system entirely | source |
| Strongest efficacy evidence | Cochrane review of 24 trials with 10,018 women contributing data, plus a network meta-analysis of 122 trials in 121,931 women | Hundreds of administration studies; the largest randomized trials in autism, obesity and trust report no benefit on their primary endpoints | source |
| Bioavailability | Intravenous by definition; intramuscular response within 3 to 5 minutes | 0.7% measured by mass spectrometry, with 47% median inaccuracy between people | source |
| Supervision | Label requires continuous observation by trained personnel in a hospital for induction and augmentation | Self-administered, unmonitored, dose per actuation often undocumented | source |
| Documented serious harms | Uterine rupture, hypertensive episodes, water intoxication with convulsions at high prolonged infusion rates, fetal and maternal deaths reported | Short-term trial side effects no different from placebo; one published case of hyponatremic encephalopathy after excessive unmonitored spray use; no long-term dataset exists | source |
| Quality assurance | Synthetic, characterized, impurity limit and preservative stated on the label | Compounded preparations are not FDA-reviewed for safety, effectiveness or manufacturing quality before dispensing | source |